Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Cisplatin versus cetuximab with definitive concurrent radiotherapy for head and neck squamous cell carcinoma: An analysis of veterans health affairs data.

Bauml JM, Vinnakota R, Anna Park YH, Bates SE, Fojo T, Aggarwal C, Di Stefano J, Knepley C, Limaye S, Mamtani R, Wisnivesky J, Damjanov N, Langer CJ, Cohen RB, Sigel K.

Cancer. 2018 Oct 20. doi: 10.1002/cncr.31816. [Epub ahead of print]

PMID:
30341983
2.

Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer.

Aggarwal C, Thompson JC, Black TA, Katz SI, Fan R, Yee SS, Chien AL, Evans TL, Bauml JM, Alley EW, Ciunci CA, Berman AT, Cohen RB, Lieberman DB, Majmundar KS, Savitch SL, Morrissette JJD, Hwang WT, Elenitoba-Johnson KSJ, Langer CJ, Carpenter EL.

JAMA Oncol. 2018 Oct 11. doi: 10.1001/jamaoncol.2018.4305. [Epub ahead of print]

PMID:
30325992
3.

Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer.

Aggarwal C, Cohen RB, Morrow MP, Kraynyak KA, Sylvester AJ, Knoblock DM, Bauml JM, Weinstein GS, Lin A, Boyer J, Sakata L, Tan S, Anton A, Dickerson K, Mangrolia D, Vang R, Dallas M, Oyola S, Duff S, Esser M, Kumar R, Weiner D, Csiki I, Bagarazzi ML.

Clin Cancer Res. 2019 Jan 1;25(1):110-124. doi: 10.1158/1078-0432.CCR-18-1763. Epub 2018 Sep 21.

PMID:
30242022
4.

Cisplatin Every 3 Weeks Versus Weekly With Definitive Concurrent Radiotherapy for Squamous Cell Carcinoma of the Head and Neck.

Bauml JM, Vinnakota R, Anna Park YH, Bates SE, Fojo T, Aggarwal C, Limaye S, Damjanov N, Di Stefano J, Ciunci C, Genden EM, Wisnivesky JP, Ferrandino R, Mamtani R, Langer CJ, Cohen RB, Sigel K.

J Natl Cancer Inst. 2018 Sep 18. doi: 10.1093/jnci/djy133. [Epub ahead of print]

PMID:
30239887
5.

Barriers to physical activity: a study of academic and community cancer survivors with pain.

Romero SAD, Brown JC, Bauml JM, Hay JL, Li QS, Cohen RB, Mao JJ.

J Cancer Surviv. 2018 Dec;12(6):744-752. doi: 10.1007/s11764-018-0711-y. Epub 2018 Sep 4.

PMID:
30182150
6.

Radiologic Pseudoprogression during Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.

Katz SI, Hammer M, Bagley SJ, Aggarwal C, Bauml JM, Thompson JC, Nachiappan AC, Simone CB 2nd, Langer CJ.

J Thorac Oncol. 2018 Jul;13(7):978-986. doi: 10.1016/j.jtho.2018.04.010. Epub 2018 May 5.

PMID:
29738824
7.

The association between fatigue and pain symptoms and decreased physical activity after cancer.

Romero SAD, Jones L, Bauml JM, Li QS, Cohen RB, Mao JJ.

Support Care Cancer. 2018 Oct;26(10):3423-3430. doi: 10.1007/s00520-018-4203-4. Epub 2018 Apr 19.

PMID:
29675547
8.

Phase I Study of Intrapleural Gene-Mediated Cytotoxic Immunotherapy in Patients with Malignant Pleural Effusion.

Aggarwal C, Haas AR, Metzger S, Aguilar LK, Aguilar-Cordova E, Manzanera AG, Gómez-Hernández G, Katz SI, Alley EW, Evans TL, Bauml JM, Cohen RB, Langer CJ, Albelda SM, Sterman DH.

Mol Ther. 2018 May 2;26(5):1198-1205. doi: 10.1016/j.ymthe.2018.02.015. Epub 2018 Feb 21.

PMID:
29550074
9.

Etirinotecan Pegol (NKTR-102) in Third-line Treatment of Patients With Metastatic or Recurrent Non-Small-cell Lung Cancer: Results of a Phase II Study.

Aggarwal C, Cohen RB, Yu E, Hwang WT, Bauml JM, Alley E, Evans TL, Langer CJ.

Clin Lung Cancer. 2018 Mar;19(2):157-162. doi: 10.1016/j.cllc.2017.10.007. Epub 2017 Oct 19.

PMID:
29129435
10.

Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.

Bagley SJ, Kothari S, Aggarwal C, Bauml JM, Alley EW, Evans TL, Kosteva JA, Ciunci CA, Gabriel PE, Thompson JC, Stonehouse-Lee S, Sherry VE, Gilbert E, Eaby-Sandy B, Mutale F, DiLullo G, Cohen RB, Vachani A, Langer CJ.

Lung Cancer. 2017 Apr;106:1-7. doi: 10.1016/j.lungcan.2017.01.013. Epub 2017 Jan 25.

PMID:
28285682
11.

Transoral Robotic Surgery-Assisted Endoscopy With Primary Site Detection and Treatment in Occult Mucosal Primaries.

Hatten KM, O'Malley BW Jr, Bur AM, Patel MR, Rassekh CH, Newman JG, Cannady SB, Chalian AA, Hodnett BL, Lin A, Lukens JN, Cohen RB, Bauml JM, Montone KT, Livolsi VA, Weinstein GS.

JAMA Otolaryngol Head Neck Surg. 2017 Mar 1;143(3):267-273. doi: 10.1001/jamaoto.2016.3419.

PMID:
27930761
12.

Scan-associated distress in lung cancer: Quantifying the impact of "scanxiety".

Bauml JM, Troxel A, Epperson CN, Cohen RB, Schmitz K, Stricker C, Shulman LN, Bradbury A, Mao JJ, Langer CJ.

Lung Cancer. 2016 Oct;100:110-113. doi: 10.1016/j.lungcan.2016.08.002. Epub 2016 Aug 16.

13.

Immunotherapy for head and neck cancer: latest developments and clinical potential.

Bauml JM, Cohen RB, Aggarwal C.

Ther Adv Med Oncol. 2016 May;8(3):168-75. doi: 10.1177/1758834016631529. Epub 2016 Feb 16. Review.

14.

PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer.

Bagley SJ, Bauml JM, Langer CJ.

Clin Adv Hematol Oncol. 2015 Oct;13(10):676-83. Review.

PMID:
27058572
15.

Post-treatment weight change in oral cavity and oropharyngeal squamous cell carcinoma.

Zhang Z, Brown JC, O'Malley BW Jr, Troxel AB, Bauml JM, Rubnitz KR, Grosso CM, Weinstein GS, Schmitz KH.

Support Care Cancer. 2016 May;24(5):2333-2340. doi: 10.1007/s00520-015-3029-6. Epub 2015 Dec 1.

16.

Do attitudes and beliefs regarding complementary and alternative medicine impact its use among patients with cancer? A cross-sectional survey.

Bauml JM, Chokshi S, Schapira MM, Im EO, Li SQ, Langer CJ, Ibrahim SA, Mao JJ.

Cancer. 2015 Jul 15;121(14):2431-8. doi: 10.1002/cncr.29173. Epub 2015 May 26.

Supplemental Content

Loading ...
Support Center